Researchers led by Duke Health have reached a major milestone in a national effort to develop a new treatment aimed at helping the body repair damaged joints at the source, accelerating momentum toward a potential commercially available therapy.

Study shows an experimental anti‑inflammatory drug was safe in older surgery patients and may reduce postoperative delirium.

Researchers at Duke University School of Medicine are investigating a potential biomarker to better detect and monitor central nervous system (CNS) involvement in Pompe disease, a metabolic disorder that leads to muscle weakness, respiratory failure, and heart problems. 

A newly published study from Duke Cancer Institute researchers sheds light on a long‑standing mystery in cancer biology and reveals a potential new path toward more targeted treatments for pancreatic and other solid tumors.

Christopher Lindsell, PhD, has been appointed vice dean for data science and AI for

Viruses infect people every day. From the common cold to influenza, COVID, and more, viruses are part of life.

In this conversation, Dr. Swamy reflects on the significant progress made over the past year as Duke adapted to national shifts in research funding, strengthened operational systems, and enhanced support for investigators. She highlights the strategic changes shaping how research is conducted at Duke, the importance of sharing the story of research through the Duke Research Saves Lives campaign, and the role of technology in transforming operations.

What if heart disease isn’t just about weak muscles but the wrong fuel? New research exploring ketones asks whether changing how the heart burns energy could transform future treatment.

David Zaas, MD, MBA, a seasoned academic health care executive and physician scientist with a long history in Durham, will be the next chief executive officer of Duke University Health System.